Clorazepate dipotassium
Tranxene (clorazepate dipotassium) is a small molecule pharmaceutical. Clorazepate dipotassium was first approved as Tranxene on 1982-01-01. It is used to treat alcohol withdrawal delirium, anxiety disorders, and partial epilepsies in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Tranxene (generic drugs available since 1987-07-17, discontinued: Gen-xene)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Clorazepate dipotassium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRANXENE | Key Therapeutics | N-017105 RX | 1982-01-01 | 1 products, RLD |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clorazepate dipotassium | ANDA | 2023-04-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alcohol withdrawal delirium | EFO_1000800 | D000430 | — |
| anxiety disorders | EFO_0006788 | D001008 | F41.1 |
| partial epilepsies | EFO_0004263 | D004828 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | 1 | — | — | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | — | 1 | — | — | 1 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | 1 | — | — | 1 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CLORAZEPATE DIPOTASSIUM |
| INN | dipotassium clorazepate |
| Description | Clorazepic acid is a 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively. It has a role as a prodrug, an anticonvulsant, an anxiolytic drug and a GABA modulator. It is a conjugate acid of a clorazepic acid anion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-] |
Identifiers
| PDB | — |
| CAS-ID | 23887-31-2 |
| RxCUI | 2353 |
| ChEMBL ID | CHEMBL2096631 |
| ChEBI ID | 3762 |
| PubChem CID | 2809 |
| DrugBank | DB00628 |
| UNII ID | 63FN7G03XY (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 227 documents
View more details
Safety
Black-box Warning
Black-box warning for: Clorazepate dipotassium
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,089 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more